CYTOKINETICS Inc. Announces ACACIA‑HCM Results Published in NEJM

What Happened

• On August 28, 2026, Cytokinetics, Incorporated (NASDAQ: CYTK) filed a Form 8‑K (Item 8.01) to announce that the full results of the ACACIA‑HCM clinical trial were presented at the European Society of Cardiology (ESC) Congress 2026 and published in the New England Journal of Medicine (NEJM). The company issued a press release in connection with this announcement, which is included as Exhibit 99.1 to the 8‑K. The filing is signed by John O. Faurescu, SVP, Deputy General Counsel & Secretary.

Key Details

• Filing date: August 28, 2026 (Form 8‑K, Item 8.01 disclosed as "Other Events").
• Event: Presentation of full ACACIA‑HCM results at ESC Congress 2026 and publication in the New England Journal of Medicine.
• Press release: Issued August 28, 2026 and incorporated as Exhibit 99.1 to the 8‑K.
• Administrative: Form 8‑K also lists Exhibit 99.1 under Item 9.01; signed by John O. Faurescu.

Why It Matters

• Publication in NEJM and presentation at ESC are major scientific and visibility milestones for a clinical‑stage drug program. These items provide peer‑reviewed dissemination of trial data to clinicians, regulators and investors.
• The 8‑K itself does not include financial results, regulatory approvals, or detailed numeric trial outcomes in the filing text; investors should review the press release and the NEJM article for the full clinical data and context.
• For investors, such publications can influence perception of a program’s scientific credibility and may affect future commercial or regulatory developments, but the filing is informational and not a statement of financial guidance or regulatory decision.